A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
NCT00620685
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Adult with RA for at least 6 months
- Stable weekly dosage of oral methotrexate 12.5- 25 mg/week
- Severe, progressive and/or uncontrolled other disease
- Chronic or recent serious infection; current infection
- Concomitant use of RA therapy other than methotrexate with some exceptions
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Mesa, Arizona
- Debary, Florida
- Lake Mary, Florida
- Tampa, Florida
- Avon, Indiana
- New Orleans, Louisiana
- Frederick, Maryland
- Columbia, Missouri
- Columbia, Missouri
- Reno, Nevada
- Cincinnati, Ohio
- Spokane, Washington
- Providencia, Santiago, RM
- Ceska Lipa,
- Praha 2,
- Praha 4,
- Incheon,
- Pusan,
- Mexico, D.f.
- Krakow,
- Poznan,
- Poznan,
- Santiago de Compostela, A Coruña
- A Coruña,
- Madrid,
- Sendai, Miyagi
- Los Angeles, California
- Palo Alto, California
- Lake Success, New York
- Rochester, New York
- Charlotte, North Carolina
- Columbus, Ohio
- Vancouver, British Columbia
- Mississauga, Ontario
- Montreal, Quebec
- Peoria, Arizona
- Daytona Beach, Florida
- Port Orange, Florida
- Overland Park, Kansas
- Overland Park, Kansas
- Frederick, Maryland
- Lansing, Michigan
- Duncansville, Pennsylvania
- Dallas, Texas
- Buenos Aires,
- Pleven,
- Sofia,
- Sofia,
- Brno,
- Praha 4,
- Mexico, D.f.
- Mexico, DF
- Bialystok,
- Bialystok,
- Krakow,
- Krakow,
- Warszawa,
- Wroclaw,
- Piestany,
- Santiago de Compostela, A Coruña
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate | |||
Official Title ICMJE | A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate | |||
Brief Summary | The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Arthritis, Rheumatoid | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 27 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | October 2008 | |||
Actual Primary Completion Date | October 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00620685 | |||
Other Study ID Numbers ICMJE | A6631005 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |